The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 4, 2003, Pages 315-324

  Kato, Masatomo ^a   Kurose, Tatsuji ^a   Oda, Tomoko ^a   Miyaji, Suguru ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APAFANT; EYE DROPS; KETOTIFEN FUMARATE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMOSIS; CONTROLLED STUDY; DRUG EFFICACY; GUINEA PIG; MALE; NONHUMAN; PROTEIN FUNCTION; PROVOCATION TEST; SCRATCHING;

EID: 0042972859     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803322279372     Document Type: Article

References (30)

1. Rankin, J.A., Hitchkock, M., Merrill, W.W., Batch, M.K., Brashler, J.R., and Askenase, P.W. IgE dependent release of leukotriene C4 from alveolar macrophages. Nature 297:329-331, 1982.
2. Rouzer, C.A., Scott, W.A., Hamill, A.L., Liu, F.T., Katz, D.H., and Cohn, Z.A. IgE immune complexes stimulate arachnidonic acid release by mouse peritoneal macrophages. Proc. Natl. Acad. Sci. 79:5656-5660, 1982.
3. Sustiel, A., and Rocklin, R. T Cell responses in allergic rhinitis. Clin. Exp. Allergy 19:11-18, 1989.
4. Gatien, J.G., Merler, E., and Colten, H.R. Allergy to ragweed antigen E: Effect of specific immunotherapy on the reactivity of human lymphocytes in vitro. Clin. Immunol. Immunopathol. 4:32-37, 1975.
5. Katz, D.H. Recent studies on the regulation of IgE antibody synthesis in experimental animals and man. Immunology 41:1-24, 1980.
6. Gauchat, J.F., Lebman, D.A., Coffman, R.L., Gascan, H., and de Vries, J.E. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin-4 to switch to IgE production. J. Exp. Med. 172:463-473, 1990.
7. Ciprandi, G.C., Buscaglia, S., Cerqueti, P.M., and Canonica, G.W. Drug treatment allergic conjunctivitis. A review of the evidence. Drugs 43:154-176, 1996.
8. Snyder, F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am. J. Physiol. 259:C697-C708, 1990.
9. Misawa, M., and Iwamura, S. Platelet-activating factor (PAF)-induced rhinitis and involvement of PAF in allergic rhinitis in guinea pigs. Jpn. J. Pharmacol. 54:217-226, 1990.
10. Tamura, G., Takishima, T., Mue, S., Makino, S., Itoh, K., Miyamoto, T., Shida, T., and Nakajima, T. Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. Adv. Exp. Med. Biol. 416:371-380, 1996.
11. Yamaguchi, S., Tomomatsu, N., Kagoshima, M., Okumoto, T., and Terasawa, M. Effect of Y-24180, an antagonist at platelet-activating factor (PAF) receptors, on IgE-mediated cutaneous reactions in mice. Inflamm. Res. 47:506-511, 1998.
12. Woodward, D.F., Nieves, A.L., Spada, C.S., Williams, L.S., and Tuckett, R.P. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Ther. 272:758-765, 1995.
13. Kato, M., Mano, H., Ota, A., Konomi, K., and Nakata, K. Platelet activating factor degradation in tear fluid from guinea pigs with allergic conjunctivitis. J. Ocular Pharmacol. Ther. 17:83-91, 2001.
14. Ukena, D., Dent, G., Birke F.W., Robaut, C., Sybrecht, G.W., and Barnes, P.J. Radioligand binding of antagonists of platelet - activating factor to intact human platelets. FEBS Letter 228:285-289, 1988.
15. Casals-Stenzel, J., Muacevic, G., and Weber, K.-H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J. Pharmacol. Exp. Ther. 241:974-981, 1987.
16. Camussi, G., Tetta, C., Coda, R., Segoloni G.P., and Vercellone, A. Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int. 25:73-81, 1984.
17. Kuraishi, Y., Nagasawa, T., Hayashi, K., and Satoh, M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur. J. Pharmacol. 275:229-233, 1995.
18. Ballas, Z., Blumenthal, M., Tinkelman, D.G., Kriz, R., and Rupp, G. Clinical evaluation of Ketrolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv. Ophthalmol. 38(Suppl):141-143, 1993.
19. Mota, I. Passive cutaneous anaphylaxis induced with mast cell sensitizing antibody. Life Sci. 12:917-927, 1963.
20. Davies, B.H., and Mullins, J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 48:519-524, 1993.
21. Netland, P.A., Leahy, C., and Krenzer, K.L. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am. J. Ophthalmol. 130:717-723, 2000.
22. Hwang, S.B., Li, C.L., Lam, M.H., and Shen, T.Y. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab. Invest. 52:617-630, 1985.
23. Humphrey, D.M., McManus, L.M., Satouchi, K., Hanahan, D.J., and Pinckard, R.N. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab. Invest. 46:422-427, 1982.
24. Nakagawa, Y., and Higashida, M. Treatment-seeking patterns and treatment compliance among patients with Japanese cedar pollen-induced allergic conjunctivitis. -Survey of ophthalmology outpatients- J. of the Eye 19:113-120, 2002.
25. Endo, K., Sumitsuji, H., Fukuzumi, T, Adachi, J., and Aoki, T. Evaluation of scratch movements by a new scratch monitor to analyze nocturnal itching in atopic dermatitis. Acta Derm. - Venereol. 77:432-435, 1997.
26. Bijak, M., Mayr, W., Rafolt, D., Tanew, A., and Unger, E. Pururitometer 2: portable recording system for the quantification of scratching as objective criterion for the pruritus. Biomed. Tech. 46:137-141, 2001.
27. Davies, M.G., and Greaves, M.W. The current status of histamine receptors in human skin: Therapeutic implications. Br. J. Dermatol. 104:601-606, 1981.
28. Kirkegaard, J., Secher, C., and Mygind, N. Effect of the HI antihistamine chlorpheniramine maleate on histamine induced symptoms in the human conjunctiva. Allergy 37:203-208, 1982.
29. Shirasaki, H., and Asakura, K. Detection of platelet-activating factor in nasal lavage fluid from patients with pollinosis and experimental animals with nasal allergy. Nippon Jibiinkoka Gakkai Kaiho 93:420-427, 1990.
30. Yanni, JM., Stephens, DJ., Parnell, DW., Spellman, JM. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J. Ocular Pharmacol. 10:665-675, 1994.